Release Date: November 26, 2025
Expiration Date: November 26, 2026
Activity Overview
This online, on-demand virtual symposium brings together renowned retina specialists to discuss the treatment of macular telangiectasia (MacTel) type 2, which is a rare, progressive retinal disease. In this educational program, these experts discuss recent innovations in approved therapy for this condition and opportunities for early detection and diagnosis.
This educational activity is an archive of the live symposium held on October 18, 2025.
Target Audience
This educational activity is directed toward retina specialists, comprehensive ophthalmologists, optometrists, and other eye care professionals involved in the management of patients with macular telangiectasia type 2.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Identify the limitations of anti-VEGF intravitreal injection therapies in the treatment of MacTel.
- Analyze emerging evidence supporting the use of novel therapies in the management of MacTel.
- Summarize the role of retina specialists in the optimal management of MacTel.
Charles C. Wykoff MD, PhD
Director of Research
Retina Consultants of Texas
Houston, TX
Disclosures: Consultant/Honoraria: 4DMT, AbbVie, Acuta, ADARx, Adverum, Alcon, Alimera, Alkeus, Allgenesis, AMC Sciences, Annexon, Apellis, Arrowhead, Ascidian, Astellas, Aviceda, Bausch + Lomb, Bayer, BioCryst, Bionic Vision, Boehringer Ingelheim, Chengdu Kanghong, Curacle, Emmecell, Eyebiotech, EyePoint, Genentech, InGel, Janssen, Kiora, Kodiak, Kowa, Nanoscope, Neurotech, NGM, Novartis, Oak Bay Bio, Ocular Therapeutix, OcuTerra, Ollin, ONL, Opthea, Opus, Osanni, Oxular, Palatin, Perceive Bio, Perfuse, Ray, Regeneron, Regenxbio, RetinAI, Roche, Samsung Bioepis, Sandoz, Sanofi, Santen, Skyline, Stealth, Sylentis, TCG Crossover, THEA, Therini, VH401,Visgenx, Zeiss; Research Grants: 4DMT, AbbVie, Adverum, AffaMed, Alexion, Alimera, Allgenesis, Amgen, Annexin, Annexon, Apellis, Ascidian, AsclepiX, Astellas, Aviceda, Avirmax, Bayer, Boehringer Ingelheim, Chengdu Origen, Clearside, Curacle, Eluminex, Eyebiotech, EyePoint, Genentech, IONIS, iRenix, Janssen, Kalaris, Kodiak, Kyoto DDD, Kyowa Kirin, Nanoscope, Neurotech, NGM, Novartis, Ocugen, Ocular Therapeutix, Oculis, OcuTerra, OliX, Ollin, Opthea, Outlook Therapeutics, Oxular, Oxurion, Perceive Bio, Pykus, Regeneron, Regenxbio, Rezolute, Roche, Shanghai Henlius, Stealth, Skyline, VH401; Stock Options (Not Owner) From Private For-Profit Entities: InGel, Ollin, ONL, Osanni, Panther, TissueGen, Visgenx, Vitranu
Diana V. Do, MD
Vice Chair of Clinical Affairs
Professor of Ophthalmology
The Byers Eye Institute
Stanford University School of Medicine
Palo Alto, CA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Apellis, Astellas, Belite Bio, LumiThera, Oculis, Regenxbio; Grant/Research Funding: Apellis, Belite Bio, LumiThera, Neurotech, Oculis, Regeneron, Regenxbio; Ownership Interests in Publicly-Traded Companies: Belite Bio, Kodiak Sciences
Dante Pieramici, MD, FASRS
Medical Director, Clinical Research
California Retina Consultants
Director
California Retina Research Foundation
Bakerfield, CA
Disclosures: Advisory: Perceive; Consultant: 4DMT, Adverum, Eyepoint, Genentech, Neurotech, Ocular Therapeutix, Opthea, Regeneron, Retina AI, Roche, Samsung, Unity; Research Funding: 4DMT, Adverum, Eyepoint, Genentech, Novartis, Ocular, Ocular Therapeutix, Opthea, Regeneron, Retina AI, Roche; Unity
Jed H. Assam, MD
Clinical Faculty
Department of Surgery
University of South Dakota
Sanford School of Medicine
Sioux Falls, SD
Disclosures: Jed H. Assam, MD, has no relevant financial relationships with ineligible companies.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here